Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;63(13):3257-3260.
doi: 10.1080/10428194.2022.2118532. Epub 2022 Sep 8.

A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML

Konstantinos Lontos  1 , Anastasia Tsagianni  1 , Mounzer Agha  1 , Anastasios Raptis  1 , Jing-Zhou Hou  1 , Rafic Farah  1 , Robert L Redner  1 , Annie Im  1 , Kathleen A Dorritie  1 , Alison Sehgal  1 , James Rossetti  1 , Nidhi Aggarwal  2 , Melissa Saul  3 , William Gooding  4 , Michael Boyiadzis  1
Affiliations

A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML

Konstantinos Lontos et al. Leuk Lymphoma. 2022 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1 A.
Figure 1 A.. Somatic mutations of the entire cohort (n=178).
Among the genes, only NPM1, DNMT3A and TP53, were associated with response to intensive induction chemotherapy. B. Probability to response to induction chemotherapy. NPM1, TP53, and cytogenetic class were used to fit a multivariate logistic model for response to the first course of chemotherapy. The presence of a TP53 mutation and poor cytogenetics, and the absence of an NPM1 mutation have a low probability of response to induction chemotherapy. The model is summarized by the C index (area under the ROC curve) and R2 (proportion of variance explained). After bootstrap validation, these statistics were reduced to 0.781 and 0.319, respectively.
Figure 2.
Figure 2.. Nomogram that can predict response to induction chemotherapy.
The nomogram is used to assign points to each of the 3 predictors (TP53, NPM1, cytogenetics). The combined points for an individual patient are then added and the total points are compared to the probability for response to induction chemotherapy. For example, a patient with NPM1 mutation, intermediate cytogenetics and no TP53 mutation has a combined 186 points and a >0.9 probability of response.
See this image and copyright information in PMC

References

    1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016. Jun 9;374(23):2209–2221. doi: 10.1056/NEJMoa1516192. - DOI - PMC - PubMed
    1. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012. Mar 22;366(12):1079–89. doi: 10.1056/NEJMoa1112304. - DOI - PMC - PubMed
    1. Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021. Feb 22;11(2):41. doi: 10.1038/s41408-021-00425-3. - DOI - PMC - PubMed
    1. Estey E, Karp JE, Emadi A, et al. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse? Leukemia. 2020. Mar;34(3):671–681. doi: 10.1038/s41375-019-0704-5. - DOI - PubMed
    1. Perl AE. The role of targeted therapy in the management of patients with AML. Blood Adv. 2017. Nov 14;1(24):2281–2294. doi: 10.1182/bloodadvances.2017009829. advisory committee for Asana Biosciences and Actinium Pharmaceuticals and has consulted for Daiichi Sankyo, Astellas, Novartis, Pfizer, Arog, Seattle Genetics, Asana Biosciences, and Actinium Pharmaceuticals. Off-label drug use: This presentation includes novel agents in clinical development that do not yet have label indications in acute myeloid leukemia (AML). The use of sorafenib, azacitidine, or decitabine for AML therapy is off label. - DOI - PMC - PubMed

Publication types